|
Program Overview: |
 |
The key clinical dilemma in acute coronary syndromes (ACS) is finding the balance between antiplatelet efficacy and increased bleeding risk for each patient. This moving target is becoming even more dynamic, as a new generation of antiplatelet agents comes to market, drug-drug interactions are suspected in common ACS regimens, and point-of-care platelet function testing becomes more prevalent in clinical settings. Will these advances bring solutions to the clinicians’ dilemmas or further complicate them? Attendees at the Cardiology Town Hall Meeting: Discussion, Questions, and Answers in the Management of Acute Coronary Syndromes will be able to get answers to their questions and voice their opinions during the discussions integrated throughout this highly interactive program. Brief presentations will review the data on each topic, and then the floor is open for discussion and debate.
Is personalized medicine ready for prime time in the catheterization lab? Will platelet function testing and new antiplatelet options translate into individualized regimens? Individualizing antiplatelet regimens will require an understanding of the emerging agents’ pharmacokinetics, determination of the optimal timing and duration of their use, and assessment of the absolute thrombotic versus hemorrhagic risk for each patient. Bedside testing for clopidogrel resistance and new insights into the risks of drug-drug interactions may also provide data needed for designing individualized ACS regimens. This symposium will discuss the potential for these advances to improve the standard of care and provide solutions to ongoing clinical dilemmas in ACS. |
Sunday, November 15, 2009
Orlando, Florida
The Peabody Orlando, Plaza E-H
Dinner: 7:00-7:30pm
Symposium: 7:30-9:00pm
Faculty
Peter Berger, MD, FACC, FAHA
Associate Chief Research Officer
Director, Center for Clinical Studies
Interventional Cardiologist
Division of Cardiology
Geisinger Health System
Danville, Pennsylvania
Paul A. Gurbel, MD
Director, Sinai Center for Thrombosis Research
Sinai Hospital of Baltimore
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
Professor of Medicine
Associate Director, Duke Heart Center-Cardiology Clinics
Director, Program for Advanced Coronary Disease
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina
Marc S. Sabatine, MD, MPH
Investigator, TIMI Study Group
Associate Physician
Division of Cardiovascular Medicine
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Agenda
| 7:00-7:30PM |
Dinner/Registration |
| 7:30-7:45PM |
Welcome and Overview: The Clinical Dilemmas in ACS
Peter Berger, MD, FACC, FAHA |
| 7:45-8:00PM |
Response Variability and Point-of-Care Platelet Function Testing
Paul A. Gurbel, MD |
| 8:00-8:10PM |
Town Hall Discussion
Moderator: Peter Berger, MD, FACC, FAHA
Paul A. Gurbel, MD
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
Marc S. Sabatine, MD, MPH |
| 8:10-8:25PM |
Safety and Efficacy of Emerging Antiplatelet Therapies
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI |
| 8:25-8:35PM |
Town Hall Discussion
Moderator: Peter Berger, MD, FACC, FAHA
Paul A. Gurbel, MD
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
Marc S. Sabatine, MD, MPH |
| 8:35-8:50PM |
The Issue of Drug-Drug Interactions
Marc S. Sabatine, MD, MPH |
| 8:50-9:00PM |
Town Hall Discussion
Moderator: Peter Berger, MD, FACC, FAHA
Paul A. Gurbel, MD
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
Marc S. Sabatine, MD, MPH |
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Identify the potential for drug-drug interactions between antiplatelet therapies and statins, proton pump inhibitors, and calcium channel blockers in patients with ACS
- Describe how platelet function testing may be incorporated into the clinical management of ACS patients to improve patient outcomes
- Describe recent safety and efficacy data on emerging pharmacologic agents for patients with ACS
- Outline the potential impact of antiplatelet response variability on clinical outcomes in patients with ACS
Target Audience
This activity is designed for cardiologists and other healthcare professionals interested in the clinical dilemmas of treating patients with ACS, including drug-drug interactions, response variability, point-of-care platelet function assays, and balancing safety and efficacy, among others.
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ACCELMED. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Americans with Disabilities Act
 |
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact ACCELMED prior to the live event at (877) 374-8323. |
This event is not part of the official Scientific Sessions 2009 as planned by the Scientific Sessions Program Committee.
Sponsored by Postgraduate Institute for Medicine
|
